Combination of | |
---|---|
Finasteride | 5α-reductase inhibitor |
Tadalafil | Phosphodiesterase 5 (PDE5) inhibitor |
Clinical data | |
Trade names | Entadfi |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH). [1] [2] [3] It contains finasteride and tadalafil. [1] It is taken by mouth. [1]
It was approved for medical use in the United States in December 2021. [1] [4]
Finasteride/tadalafil is indicated to treat benign prostatic hyperplasia (BPH) in men. [1]
Combination of | |
---|---|
Finasteride | 5α-reductase inhibitor |
Tadalafil | Phosphodiesterase 5 (PDE5) inhibitor |
Clinical data | |
Trade names | Entadfi |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH). [1] [2] [3] It contains finasteride and tadalafil. [1] It is taken by mouth. [1]
It was approved for medical use in the United States in December 2021. [1] [4]
Finasteride/tadalafil is indicated to treat benign prostatic hyperplasia (BPH) in men. [1]